Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
3(38%)
Results Posted
0%(0 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
2
25%
Ph phase_1
6
75%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
6(75.0%)
Phase 2Efficacy & side effects
2(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Recruiting2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (75.0%)
Phase 22 (25.0%)

Trials by Status

recruiting225%
terminated225%
completed338%
active_not_recruiting113%

Recent Activity

3 active trials
Showing 5 of 8
terminatedphase_1

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

NCT06245941
active_not_recruitingphase_2

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

NCT05020652
completedphase_1

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

NCT06024915
recruitingphase_1

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

NCT06122831
completedphase_1

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

NCT04941404
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06245941Phase 1

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Terminated
NCT05020652Phase 2

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Active Not Recruiting
NCT06024915Phase 1

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Completed
NCT06122831Phase 1

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Recruiting
NCT04941404Phase 1

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Completed
NCT06388759Phase 1

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Terminated
NCT06300320Phase 2

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Recruiting
NCT05982106Phase 1

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8